<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243658</url>
  </required_header>
  <id_info>
    <org_study_id>OX02</org_study_id>
    <nct_id>NCT01243658</nct_id>
  </id_info>
  <brief_title>&quot;The Effects of Oxytocin on Patients With Borderline Personality Disorder&quot;</brief_title>
  <official_title>&quot;The Effects of Oxytocin on Patients With Borderline Personality Disorder&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Markus Heinrichs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine if&#xD;
      oxytocin, compared to placebo shows any additional effect on the therapy achievements&#xD;
      (outcome) of patients with borderline personality disorder, who receive an in-patient&#xD;
      standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
      Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in&#xD;
      patients with borderline personality disorder. Comparison of the effects of Oxytocin on&#xD;
      patients with BPD and major depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPD Symptoms</measure>
    <time_frame>BPD Symptoms</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Effects of Oxytocin on Borderline Personality Disorder</condition>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gender: Both, male and female&#xD;
&#xD;
          -  Minimum Age: 18 Years&#xD;
&#xD;
          -  Maximum Age: 50 Years&#xD;
&#xD;
          -  Borderline personality disorder or major depression (clinical control group)&#xD;
&#xD;
          -  Mini Mental Status Test &gt; 27 (capacity to consent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic or acute somatic health problems&#xD;
&#xD;
          -  Schizophrenia&#xD;
&#xD;
          -  Bipolar affective disorder&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast feeding&#xD;
&#xD;
          -  neurological disorder&#xD;
&#xD;
          -  allergy to antidegradants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Heinrichs, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institut f체r Psychologie der Univerist채t Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert-Ludwigs-Universit채t-Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-W체rtemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Markus Heinrichs</investigator_full_name>
    <investigator_title>Prof. Dr. Markus Heinrichs</investigator_title>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>BPD</keyword>
  <keyword>Borderline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

